1487P Extended follow-up at 42 months of atezolizumab–bevacizumab in advanced HCC: Insights from the CHIEF prospective study

作者：Manon Allaire, E.M. Thiam, Julien Edeline, P. Merle, J.F. Blanc, G. Amaddeo, Thomas Uguen, Thomas Decaens, N. Carrie Ganne, Christine Sylvain, M. Bouattour, Ghassan Riachi, S. Cattan, Xavier Adhoute, M. Gratien, C. Laurent, A. Koudjou-Sonegueng, G. Ducournau, O. Ganry, Éric Nguyen-Khac · 发表于：Annals of Oncology · 年份：2025 · DOI：10.1016/j.annonc.2025.08.2117 · 被引用次数：1 · 研究领域：HER2/EGFR in Cancer Research、Cancer Immunotherapy and Biomarkers、Colorectal Cancer Treatments and Studies